The gap between how fast new pathogens emerge and how slowly traditional vaccines are developed has never felt more consequential. A comprehensive review in the Journal of Microbiological Methods now charts a rigorous scientific roadmap for closing that gap through pan-pathogen vaccinology — an approach designed to deliver cross-protective immunity against multiple pathogens simultaneously, rather than one disease at a time.
The review draws a careful conceptual distinction between three often-conflated terms: universal vaccines (targeting all strains of a single pathogen family), broad-spectrum vaccines (covering multiple related pathogens), and pan-pathogen vaccines (aiming for immunity across unrelated disease threats). Operating within the One Health framework — which treats human, animal, and environmental health as inseparable — the authors map specific strategies for identifying conserved antigenic epitopes using comparative genomics, evolutionary biology, and immunoinformatics. Mechanistically, the review details how cross-protective immunity arises from the interplay of broadly neutralizing antibodies, CD4/CD8 T-cell responses, mucosal immunity, and trained innate immunity. Real-world examples, including rVSV-Ebola and Nipah virus vaccine candidates, anchor the theoretical architecture in active development pipelines. Advanced platforms — mRNA, viral vectors, protein subunits, and nanoparticles — are evaluated for their suitability in this multi-target paradigm.
This review arrives at a critical inflection point. Post-COVID, there is enormous institutional momentum behind platform-based vaccine technology, but the scientific community still lacks consensus on what broadly protective immunity actually requires at the molecular level. The pan-pathogen framework presented here is intellectually ambitious, synthesizing immunology, genomics, and ecology under a single preparedness umbrella. Its primary limitation is that it remains a review — the translational gap between elegant epitope discovery and durable human immunity across divergent pathogens is substantial, and no pan-pathogen vaccine has yet reached late-stage clinical validation. Still, as a conceptual and strategic synthesis, this is a genuinely useful contribution to the pandemic preparedness literature, consolidating disparate research threads into a framework that could guide grant priorities and platform development decisions over the coming decade.